A Multicenter Study to Evaluate the Cios Spin and the Ion Endoluminal System for Pulmonary Nodule Biopsy
NCT ID: NCT05562895
Last Updated: 2025-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
155 participants
OBSERVATIONAL
2022-12-31
2025-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Subjects with biopsy of pulmonary nodule using Ion Endoluminal System and Cios Spin
Subjects in which a pulmonary nodule biopsy was attempted or performed with the integrated Ion Endoluminal System and Cios Spin
Ion Endoluminal System and Cios Spin
Integrated version of the Ion Endoluminal System and Cios Spin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ion Endoluminal System and Cios Spin
Integrated version of the Ion Endoluminal System and Cios Spin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pulmonary nodule biopsy attempted/performed using the Ion Endoluminal System and Cios Spin 3D imaging.
* Pulmonary nodule ≤2 cm in largest diameter.
* Subject able to understand and adhere to study requirements and provide informed consent.
Exclusion Criteria
* Nodule is a pure ground glass opacity.
* Plan to biopsy multiple nodules.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Intuitive Surgical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roberto Casal, MD
Role: PRINCIPAL_INVESTIGATOR
MD Anderson
Bryan Husta, MD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
University of California San Diego, Hillcrest Medical Center
San Diego, California, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
South Austin Hospital
Austin, Texas, United States
MD Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ISI-ION-002
Identifier Type: -
Identifier Source: org_study_id